Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects

Phase I, single-blind, randomised, placebo- and active-controlled parallel group study

Abstract

Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single-blind, randomized, placebo- and active-controlled parallel group study investigated whether tafenoquine at supratherapeutic and therapeutic concentrations prolonged cardiac repolarization in healthy volunteers.

Citation

Green, J.A.; Patel, A. K.; Patel, B. R.; Hussaini, A.; Harrell, E. J.; McDonald, M. J.; Carter, N.; Mohamed, K.; Duparc, S.; Miller, A.K. Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects. The Journal of Clinical Pharmacology 54 (9) 995-1005. [DOI: 10.1002/jcph.302]

Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects

Published 5 December 2014